Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of RVG-SCMH1-Evs treatment on photothrombotic (PT) stroke mice

ABSTRACT: Metabolic dysfunction is considered a key event after ischemic stroke. However, the underlying mechanisms of metabolic disorders in cerebral ischemia is unknown. Circular RNA SCMH1 (circSCMH1), a circular RNA that has been reported to function in brain repair after stroke, was confirmed to be involved in metabolic disorders. circSCMH1 was delivered by rabies virus glycoprotein (RVG)-modified sxtracellular vesicle. Mechanistically, circSCMH1 decreased kynurenine 3-monooxygenase (KMO) expression, a key enzyme in kynurenine metabolism. Our findings suggested that circSCMH1 inhibited KMO expression, providing insight into the mechanism by which circSCMH1 promotes stroke recovery.

ORGANISM(S): Mus musculus

PROVIDER: GSE261613 | GEO | 2024/05/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-Seq data on KMO inhibitor (CHDI-00340246) subchronic treated R6/2 mice.

Project description:Dysregulation of the kynurenine (Kyn) pathway has been associated with the progression of Huntington's disease (HD). In particular, elevated levels of the kynurenine metabolites 3-hydroxy kynurenine (3-OH-Kyn) and quinolinic acid (Quin), have been reported in the brains of HD patients as well as in rodent models of HD. The production of these metabolites is controlled by the activity of kynurenine mono-oxygenase (KMO), a mitochondrial outer membrane enzyme which catalyzes the synthesis of 3-OH-Kyn from Kyn. Thus inhibiting KMO is expected to produce a beneficial effect in Huntington's Disease (HD) patients, hopefully reversing their phenotype to match healthy subjects. To test this effect, we chronically treated a mouse model of HD (R6/2, a transgenic mouse model of HD which contains a human HTT gene containing 90 CAG repeats) and wild type mice with a KMO inhibitor for 8 weeks, and separately used a mock treatment on both the transgenic mice and wild type mice. The goal of this project is to analyze the RNA-seq data and find gene expression changes associated with the KMO inhibitor.

2017-10-30 | GSE105158 | GEO

RNAseq data on single dose KMO inhibitor (CHDI-00340246) treated R6/2 mice.

Project description:Dysregulation of the kynurenine (Kyn) pathway has been associated with the progression of Huntington's disease (HD). In particular, elevated levels of the kynurenine metabolites 3-hydroxy kynurenine (3-OH-Kyn) and quinolinic acid (Quin), have been reported in the brains of HD patients as well as in rodent models of HD. The production of these metabolites is controlled by the activity of kynurenine mono-oxygenase (KMO), a mitochondrial outer membrane enzyme which catalyzes the synthesis of 3-OH-Kyn from Kyn. Thus inhibiting KMO is expected to produce a beneficial effect in Huntington's Disease (HD) patients, hopefully reversing their phenotype to match healthy subjects. To test this effect, we acutely treated a mouse model of HD (R6/2, a transgenic mouse model of HD which contains a human HTT gene containing 90 CAG repeats) and wild type mice with a KMO inhibitor, and separately used a mock treatment on both the transgenic mice and wild type mice. The goal of this project is to analyze the RNA-seq data and find gene expression changes associated with the KMO inhibitor

2017-10-30 | GSE106161 | GEO

Tumor-derived kynurenine induces Siglec-15 expression and promotes CD8+T cell exhaustion in oral squamous cell carcinoma

Project description:Metabolic deregulation and immune escape are pivotal hallmarks of cancer; however, the profile of metabolic reprogramming in oral squamous cell carcinoma (OSCC) and how it drives immune escape remain unclear. We identified significant metabolic disorders in OSCC. Amino acid metabolism, especially tryptophan/kynurenine metabolism, was altered. Here, we found that kynurenine promotes migration, invasion, and proliferation in vitro and in vivo. In addition, most immune checkpoints were upregulated in patients with high kynurenine levels. We then identified that kynurenine can promote Siglec-15 expression via AhR activation. Furthermore, tumor-derived kynurenine can directly exhaust CD8+ T cells, whereas blocking of kynurenine transporters reversed this effect. Moreover, we found that ectopic expression of Siglec-15 can promote immune escape in tumor microenvironment (TME) by suppressing T cell infiltration and inducing CD8+ T cell exhaustion in vivo, while targeting AhR reduces kynurenine-mediated immune escape. Finally, we design NH2-MSNs nanoparticles to deliver Siglec-15 small interfering RNA, which successfully remodels the TME and enhances anti-PD-1 efficacy in tumor-bearing immunocompetent mice. Clinically, Siglec-15 expression is correlated with AhR expression and high infiltration of exhausted CD8+ T cells. These findings reveal that the Kyn/AhR/Siglec-15 signaling pathway is a novel immunometabolism mechanism in OSCC, thus opening a new therapeutic avenue for metabolic immunotherapy.

2024-07-03 | GSE222673 | GEO

Photothrombotic Cerebral Stroke as a Model of Post-Stroke Seizures/Epilepsy in aged mice

Project description:Stroke is a prevalent disorder representing the third leading cause of death and major cause of disability. Post-stroke epilepsy (PSE) has been recognized as a common clinical issue after stroke, accounting for 30-40% of the causes of epilepsy among older adults. In this study, we determined GABAA receptor-mediated seizure susceptibility after PT cerebral stroke in aged mice. Young adult mice around 10 weeks of age are widely used in stroke experiments. However, as most strokes are diagnosed in the elderly and PSE has been recognized as a common clinical incidence after stroke, we utilized photothrombosis (PT) model of cerebral ischemia and examined seizure susceptibility and brain injury using combined behavioral (video) and EEG monitoring and histological (MRI) assessments. To investigate GABAA receptor-mediated convulsive/non-convulsive seizures, lower-doses of pentylenetetrazol (PTZ) was injected. PTZ susceptibility in aging mice increased compared to young adults. One month after PT stroke, aged PT stroke mice exhibited severe convulsive seizures (late-onset). These findings exhibited the increase of GABAA receptor-mediated seizures susceptibility in PT stroke aging mice, but not in young adults.

2023-11-27 | GSE241528 | GEO

Microbiota alteration is associated with the development of stress-induced despair behavior

Project description:Depressive disorders often run in families, which, in addition to the genetic component, may point to the microbiome as a causative agent. Here, we employed a combination of behavioral, molecular and computational techniques to test the role of the microbiota in mediating despair behavior. In chronically stressed mice displaying despair behavior, we found that the microbiota composition and the metabolic signature dramatically change. Specifically, we observed reduced Lactobacillus and increased circulating kynurenine levels as the most prominent changes in stressed mice. Restoring intestinal Lactobacillus levels was sufficient to improve the metabolic alterations and behavioral abnormalities. Mechanistically, we identified that Lactobacillus-derived reactive oxygen species may suppress host kynurenine metabolism, by inhibiting the expression of the metabolizing enzyme, IDO1, in the intestine. Moreover, maintaining elevated kynurenine levels during Lactobacillus supplementation diminished the treatment benefits. Collectively, our data provide a mechanistic scenario for how a microbiota player (Lactobacillus) may contribute to regulating metabolism and resilience during stress.

2020-07-08 | GSE153992 | GEO

Gene expression profiles of cerebral cortice from sham- and X-ray-irradiated mice after photothrombotic strokes

Project description:Current study aims to study the gene expression change after photothrombotic strokes, and the potential beneficial effects of whole-body X-ray irradiation on stroke mice

2023-12-31 | GSE244016 | GEO

The transcriptome analysis of Peri-infarct areas of infarction for sham, PT, and Pushen treatment

Project description:We investigated the functional recovery of in ischemic stroke by Photothrombotic stroke (PT) model. RNA-Seq of the peri-infarct cortex at 28 day after PT to clarify the potential mechanisms of pushen capsule against ischemic stroke. Pushen (drug approval number: Z20040074; batch number: 20082403; Suzhong pharma) was dissolved in the vehicle of ultrapure water, and it was administered by oral gavage at 24 hours after surgery continuously for 28 days. Mice in the Sham and Vehicle group were administered with a vehicle of ultrapure water equal to the Pushen group. By applying the cutoﬀs of P <0.05 and |log2 (fold change)|>1, 2369 differentially expressed genes (DEGs) were identified between sham vs PT, and 231 differentially expressed genes (DEGs) were identified between PT vs Pushen.

2023-06-05 | GSE207034 | GEO

Transcriptomic and proteomic multi-model global gene expression analysis reveals regulatory signatures during ischemia stroke (photothrombotic internal ischemia stroke)

Project description:The transcriptomes of focal region in C57BL/6 mice after photothrombotic internal ischemia stroke generated by RNA-sequencing, using Illumina

2024-07-01 | GSE134110 | GEO

Transcriptomic and proteomic multi-model global gene expression analysis reveals regulatory signatures during ischemia stroke (photothrombotic cerebral ischemia stroke)

Project description:The transcriptomes of focal region in C57BL/6 mice after photothrombotic cerebral ischemia stroke generated by RNA-sequencing, using Illumina

2024-07-01 | GSE133897 | GEO

Gene expression analysis of the human glioma cell line U87MG

Project description:Identification of genes and pathways regulated by kynurenine in human glioma cells Total RNA from U87MG cells was extraced after 8h or 24h of treatment with 100µM kynurenine and compared to untreated control.

2010-11-11 | E-GEOD-25272 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data